Key result
A3P5PS, a P2Y1 receptor antagonist, displaced 27% of ADP analogue binding and inhibited platelet aggregation, demonstrating that P2Y1 activation is essential but not sufficient alone for aggregation.
Population
Human platelets (cDNA library and functional assays)
Design
Preclinical
Authors
Loading...
Supports dual P2Y receptor requirement for ADP aggregation; leaves open low-affinity receptor identification for human antithrombotic targets.
ADP-induced platelet aggregation requires the simultaneous activation of both the P2Y1 receptor and another low-affinity ADP receptor, as neither can trigger aggregation alone.
Savi et al. (1998) studied Platelet activation. A3P5PS (P2Y1 receptor antagonist) was evaluated on Platelet binding, shape change, calcium increase, and aggregation. A3P5PS, a P2Y1 receptor antagonist, displaced 27% of ADP analogue binding and inhibited platelet aggregation, demonstrating that P2Y1 activation is essential but not sufficient alone for aggregation.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: